NIKKEI 225
37,068.35 -1,011.35 (-2.65%) HANG SENG
16,172.40 -213.47 (-1.30%) CRUDE OIL
84.01 +1.28 (+1.55%) GOLD FUTURES
2,397.20 -0.80 (-0.03%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
49,914.59 +651.30 (+1.32%)
Zymeworks Inc. (ZYME)
After hours:
| Previous close | 8.85 |
| Open | 8.79 |
| Bid | 8.65 x 100 |
| Ask | 8.69 x 200 |
| Day's range | 8.60 - 8.93 |
| 52-week range | 6.01 - 13.14 |
| Volume | |
| Avg. volume | 574,269 |
| Market cap | 611.826M |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.72 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.63 |
GlobeNewswireZymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results a
- GlobeNewswire
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, California April 5-10, 2024
- GlobeNewswire
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to its board of directors effective April 2, 2024. “Dr. Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and
